Unity Biotechnology
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The last earnings update was 45 days ago. More info.
Add to Portfolio Compare Print
- Unity Biotechnology has significant price volatility in the past 3 months.
9U9 Share Price and Events
7 Day Returns
1 Year Returns
9U9 Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Unity Biotechnology (9U9) | 1.1% | -10.4% | -37.9% | - | - | - |
| DE Biotechs | -2.4% | 1.8% | -7.7% | -10.2% | 51.2% | 10.1% |
| DE Market | 1.8% | 4.2% | 7.4% | -6% | 10.1% | 15.4% |
1 Year Return vs Industry and Market
- No trading data on 9U9.
- No trading data on 9U9.
9U9 Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Unity Biotechnology. This is due to cash flow or dividend data being unavailable. The share price is €7.07.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Unity Biotechnology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Unity Biotechnology's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $-2.70 |
| NasdaqGS:UBX Share Price ** | NasdaqGS (2019-04-18) in USD | $8.01 |
| Europe Biotechs Industry PE Ratio | Median Figure of 30 Publicly-Listed Biotechs Companies | 22.44x |
| Germany Market PE Ratio | Median Figure of 422 Publicly-Listed Companies | 19.59x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Unity Biotechnology.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:UBX Share Price ÷ EPS (both in USD) = 8.01 ÷ -2.70 |
-2.96x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unity Biotechnology is loss making, we can't compare its value to the Europe Biotechs industry average.
- Unity Biotechnology is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does
Unity Biotechnology's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -2.96x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts |
Not available |
| Europe Biotechs Industry PEG Ratio | Median Figure of 22 Publicly-Listed Biotechs Companies | 1.3x |
| Germany Market PEG Ratio | Median Figure of 270 Publicly-Listed Companies | 1.57x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Unity Biotechnology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Unity Biotechnology's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $3.79 |
| NasdaqGS:UBX Share Price * | NasdaqGS (2019-04-18) in USD | $8.01 |
| Germany Biotechs Industry PB Ratio | Median Figure of 15 Publicly-Listed Biotechs Companies | 3.71x |
| Germany Market PB Ratio | Median Figure of 570 Publicly-Listed Companies | 1.84x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:UBX Share Price ÷ Book Value per Share (both in USD) = 8.01 ÷ 3.79 |
2.11x |
* Primary Listing of Unity Biotechnology.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unity Biotechnology is good value based on assets compared to the DE Biotechs industry average.
Value checks
We assess Unity Biotechnology's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Unity Biotechnology has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
9U9 Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Unity Biotechnology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Unity Biotechnology's earnings growth to the Germany market average as no estimate data is available.
- Unity Biotechnology's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| DB:9U9 Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts | -137.5% |
| Germany Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 47.5% |
| Germany Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 26% |
| Germany Market Earnings Growth Rate | Market Cap Weighted Average | 11.5% |
| Germany Market Revenue Growth Rate | Market Cap Weighted Average | 4.8% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | ||||
| 2020-12-31 | 0 | 1 | ||
| 2019-12-31 | 0 | 1 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | -57 | -76 | |
| 2018-09-30 | 1 | -55 | -67 |
| 2018-06-30 | 1 | -51 | -60 |
| 2018-03-31 | 1 | -42 | -52 |
| 2017-12-31 | 1 | -38 | -45 |
| 2016-12-31 | -16 | -30 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
All data from Unity Biotechnology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | ||||
| 2020-12-31 | ||||
| 2019-12-31 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | -2.70 |
| 2018-09-30 | -3.59 |
| 2018-06-30 | -6.61 |
| 2018-03-31 | -15.78 |
| 2017-12-31 | -13.97 |
| 2016-12-31 | -11.42 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Unity Biotechnology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Unity Biotechnology's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Unity Biotechnology has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
9U9 Past Performance
How has Unity Biotechnology performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Unity Biotechnology does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
- Unable to compare Unity Biotechnology's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Unity Biotechnology's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Unity Biotechnology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | -76.40 | 16.02 | ||
| 2018-09-30 | 1.38 | -67.03 | 14.27 | |
| 2018-06-30 | 1.38 | -60.43 | 12.36 | |
| 2018-03-31 | 1.38 | -51.86 | 11.00 | |
| 2017-12-31 | 1.38 | -44.66 | 9.62 | |
| 2016-12-31 | -30.40 | 5.14 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Unity Biotechnology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Unity Biotechnology has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Unity Biotechnology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Unity Biotechnology's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Unity Biotechnology has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
9U9 Health
How is Unity Biotechnology's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Unity Biotechnology's finances.
The net worth of a company is the difference between its assets and liabilities.
- Unity Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Unity Biotechnology's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Unity Biotechnology has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Unity Biotechnology Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 160.69 | 0.00 | 171.14 |
| 2018-09-30 | 179.52 | 0.00 | 177.81 |
| 2018-06-30 | 195.07 | 0.00 | 185.97 |
| 2018-03-31 | 130.28 | 0.00 | 134.04 |
| 2017-12-31 | 90.84 | 0.00 | 86.51 |
| 2016-12-31 | 89.55 | 0.00 | 89.29 |
- Unity Biotechnology has no debt.
- Unity Biotechnology has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Unity Biotechnology has sufficient cash runway for more than 3 years based on current free cash flow.
- Unity Biotechnology has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 45.9% each year.
Financial health checks
We assess Unity Biotechnology's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Unity Biotechnology has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
9U9 Dividends
What is Unity Biotechnology's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Unity Biotechnology
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Unity Biotechnology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Unity Biotechnology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.9% |
| Germany Market Average Dividend Yield | Market Cap Weighted Average of 326 Stocks | 3% |
| Germany Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| Germany Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| Germany Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-12-31 | 0.00 | 2.00 |
| 2020-12-31 | 0.00 | 2.00 |
| 2019-12-31 | 0.00 | 2.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Unity Biotechnology has not reported any payouts.
- Unable to verify if Unity Biotechnology's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Unity Biotechnology's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Unity Biotechnology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Unity Biotechnology has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
9U9 Management
CEO
| COMPENSATION | $4,026,896 |
| AGE | 56 |
| TENURE AS CEO | 2.5 years |
CEO Bio
Mr. Keith R. Leonard, Jr., M.S., M.B.A., serves as a Venture Partner at Arch Venture Partners, L.P. Mr. Leonard serves as the Executive Chairman and Chief Executive Officer of Unity Biotechnology, Inc. Mr. Leonard has more than 20 years of experience in the pharmaceutical industry. He serves as the President and Chief Executive Officer at AESTHERx Inc. He serves at UCLA Venture Capital Fund. He served as the Chief Executive Officer and President of Kythera Biopharmaceuticals, Inc from August 2005 to October 1, 2015. He co-founded Kythera Biopharmaceuticals, Inc in 2005. He served as a Senior Vice president and General Manager at Amgen Europe and was responsible for all commercial operations in 28 countries. From May 1995 to August 1995, Mr. Leonard was responsible to help set up the company's manufacturing operations. His career at Amgen Europe included establishing Amgen's presence in rheumatology with the creation of the Rheumatology Business Unit, Head of Information Management and leadership roles in Sales and Marketing, Engineering, Operations and Finance. Mr. Leonard is a 13-year Veteran of Amgen Inc. He expanded its operations into 11 additional countries and oversaw numerous successful product launches. As a Vice President for its rheumatology business unit, he prepared the launch of arthritis drug Kineret. He has been the Chairman at Sienna Biopharmaceuticals, Inc. since January 2016. He has been a Director at Intuitive Surgical, Inc. since January 28, 2016 and Laboratoris Sanifit, S.L. since May 2016. Mr. Leonard served as a Director of Affymax, Inc. from December 2007 to June 4, 2013. He served as an Independent Director of Anacor Pharmaceuticals, Inc. from May 30, 2014 to June 24, 2016. Mr. Leonard served as a Director of Kythera Biopharmaceuticals, Inc from August 2005 to October 1, 2015. He served as an Independent Director of ARYx Therapeutics, Inc. from September 2005 to February 1, 2011. He was formerly an active duty officer in the US Navy. Mr. Leonard received a Master of Business Administration from The Anderson School of Management, University of California, Los Angeles between 1993 to 1995, a Master of Science in Mechanical Engineering from University of California, Berkeley between 1988 to 1990, a Bachelor of Arts in History from University of Maryland, College Park between 1985 to 1987 and a Bachelor of Science in Engineering from University of California, Los Angeles between 1979 to 1984.
CEO Compensation
- Insufficient data for Keith to compare compensation growth.
- Keith's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the Unity Biotechnology management team in years:
- The tenure for the Unity Biotechnology management team is about average.
Management Team
Keith Leonard
Executive Chairman & CEO
$4M
56
2.5 yrs
Ned David
Co-Founder
$3M
50
3.3 yrs
Bob Goeltz
Chief Financial Officer
$1M
45
1.6 yrs
Jan van Deursen
8.3 yrs
Judy Campisi
8.3 yrs
Daohong Zhou
8.3 yrs
Douglas Rich
Senior Vice President of Operations
49
2 yrs
Dan Marquess
Chief Scientific Officer
49
3.3 yrs
Tammy Tompkins
General Counsel & Corporate Secretary
53
1.8 yrs
Camille Landis
Senior Vice President of Corporate Development
0.9 yrs
Board of Directors Tenure
Average tenure and age of the Unity Biotechnology board of directors in years:
- The tenure for the Unity Biotechnology board of directors is about average.
Board of Directors
Keith Leonard
Executive Chairman & CEO
$4M
56
3.3 yrs
Ned David
Co-Founder
$3M
50
7.4 yrs
Graham Cooper
Director
$195K
48
2 yrs
David Lacey
Director
66
1.2 yrs
Paul Berns
Director
51
1.1 yrs
Bob Nelsen
Director
56
7.4 yrs
Kristina Burow
Director
45
7.4 yrs
Cami Samuels
Director
47
4.1 yrs
Margo Roberts
Director
63
0.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Unity Biotechnology's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Unity Biotechnology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
9U9 Company Info
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Details
| Name: | Unity Biotechnology, Inc. |
| 9U9 | |
| Exchange: | DB |
| Founded: | 2009 |
| $305,248,589 | |
| 42,856,993 | |
| Website: | http://www.unitybiotechnology.com |
| Address: |
Unity Biotechnology, Inc. 3280 Bayshore Boulevard, Suite 100, Brisbane, California, 94005, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | UBX | Common Stock | Nasdaq Global Select | US | USD | 03. May 2018 | |
| DB | 9U9 | Common Stock | Deutsche Boerse AG | DE | EUR | 03. May 2018 | |
| LSE | 0YC0 | Common Stock | London Stock Exchange | GB | USD | 03. May 2018 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/20 22:16 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2019/04/10 |
| Last earnings filing: | 2019/03/06 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
